{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004173","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.253771+00:00","generated_at":"2026-06-20T18:18:02.208962+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"IO Biotech: Phase 3 melanoma trial continues; Phase 2 lung cancer shows 4 partial responses; $142.7M cash","bullets":["IDMC recommends Phase 3 melanoma trial continue without changes; enrolling at >80 sites globally.","Initial Phase 2 basket data: 9 evaluable NSCLC patients: 4 partial responses, 4 stable disease, 1 progressive disease.","New investigator-initiated study with Johns Hopkins for SCCHN expected H1 2023; total 4 IITs ongoing.","Preliminary cash $142.7M at Dec 31, 2022; expected to fund operations into mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004173","json":"https://secwatch.observer/filing/0001193125-23-004173.json","markdown":"https://secwatch.observer/filing/0001193125-23-004173.md","text":"https://secwatch.observer/filing/0001193125-23-004173.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523004173/0001193125-23-004173-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523004173/d448682d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:18:02.208962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}